The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

Nanjing Medical University

Status: Enrolling

Conditions: Coronary Heart Disease, Susceptibility to, 1

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT05945394

20230503

Details and patient eligibility

About

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Full description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

Enrollment: 800 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with suspected coronary heart disease
2. patients received coronary angiography

Exclusion criteria

1. NYHA III-IV
2. malignant tumor
3. acute infection
4. thyroid dysfunction

Trial design

800 participants in 1 patient group

Patients with suspected CHD who experienced CAG

Description:

Patients with suspected coronary heart disease who experienced coronary angiography

Treatment:

Other: No intervention